Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitis

Inventors: Pieter Rottiers (De Pinte, BE); Klaas Vandenbroucke (Ghent, BE)

Assignee: Actogenix N.V.

C07K16/241 C07K2317/569

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,017,662
App. No.: 12/065,335
Granted: Apr 28, 2015
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Treatments for chronic enterocolitis are disclosed. More specifically, methods for administration of pharmaceutical compositions that include anti-TNF-alpha antibody producing lactic acid microorganisms, such as Lactobacillus sp. and Saccharomyces sp., are disclosed for the treatment of chronic enterocolitis.

Claims (2)

1. A method of treating inflammatory bowel disease (IBD) by orally administering a therapeutically effective amount of an anti-TNFα VHH producing Lactococcus lactis to an individual in need thereof, wherein said anti-TNFα VHH is a bivalent antibody.

2. The method according to claim 1 , wherein said IBD is selected from the group consisting of chronic colitis, Crohn's disease and ulcerative colitis.

Assignments (4)

CHANGE OF NAME Recorded Jan 28, 2016

From: ACTOGENIX NV

To: INTREXON ACTOBIOTICS NV

Reel/Frame 037627/0463 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2015

From: ABLYNX N.V.

To: ACTOGENIX N.V.

Reel/Frame 035286/0887 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2010

From: ACTOGENIX N.V.

To: ACTOGENIX N.V.; ABLYNX N.V.